Is albuminuria reduction an independent factor to predict a decrease in cardiovascular risk?;Réduire l'albuminurie: Est-ce un facteur indépendant de diminution du risque cardiovasculaire?

Medecine des Maladies Metaboliques

Volumn 4, Issue 4, 2010, Pages 441-447

  Marre, M ^a,b   Sauvanet, J P ^c  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Albuminuria; cardiovascular risk; diabetic nephropathy; microalbuminuria; renin angiotensin system; Type 2 diabetes

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; HEART FAILURE; HUMAN; KIDNEY DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 78649959126     PISSN: 19572557     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1957-2557(10)70090-0     Document Type: Article

References (38)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. New Engl J Med 1984;310:356-60.
2. Mogensen CE. Microalbuminuria, a predictor of proteinuria and early mortality in NIDDM. Diab Nutr Metab 19990;3(suppl. 1):77-86.
3. Fagot-Campagna A, Fosse S, Roudier R, et al; Comité scientifique d'Entred. Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine: d'importantes évolutions entre Entred 2001 et Entred 2007. Bull Épidémiol Hebd (BEH) 2009;42-43:464-9.
4. AFSSAPS-HAS. Recommandation Professionnelle. Traitement médicamenteux du diabète de type 2 (Actualisation). Novembre 2006. Recommandation de Bonne Pratique (Synthèse, Recommandation et Argumentaire). Diabetes Metab 2007;33(1-cahier 2):1S1-1S105. www.has-sante.fr
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
6. [Erratum in: Lancet 1999;354:602].
7. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
8. De Zeeuw D. Should albuminuria be a therapeutic target in patients with hypertension and diabetes? Am J Hypertens 2004;17:11S-15S.
9. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy: their effects on proteinuria may be independent of their effects on blood pressure. BMJ 1992;304:327-8.
10. Cordonnier DJ, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabetes mellitus. Drugs 2001;61:1883-92.
11. Passa P, Chatellier G; Diab-Hycar Study Group. The DIAB-HYCAR study. Diabetologia 1996;39:1662-7.
12. Lièvre M, Marre M, Chatellier G, et al. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. Control Clin Trials 2000;21:383-96.
13. Marre M, Lièvre M, Chatellier G, et al; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, doubleblind, placebo-controlled trial (the DIABHYCAR study). BMJ 2004;328:495-9.
14. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
15. [Erratum in: N Engl J Med 2000;342:748;
16. N Engl J Med 2000;342:1376].
17. Dagenais GR, Yusuf S, Bourassa MG, et al; HOPE Investigators. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104:522-6.
18. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
19. [Erratum in: Lancet 2000;356:860].
20. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
21. Parving HH, Lehnert H, Bröchner-Mortensen J, et al; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
22. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
23. ATLANTIS Study Group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23:1823-9.
24. Lonn E, Yusuf S, Dzavik V, et al, SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
25. Lonn E. Dose response of ACE inhibitors: implications of the natural history of the SECURE trial. Curr Control Trials Cardiovas Med 2001;2:155-9.
26. Mathew J, Sleight P, Lonn E; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
27. Lonn E, Mathew J, Pogue J, et al; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prev Rehabil 2003;10:420-8. (Pubitemid 39127674)
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
29. Pfeffer MA, Swedberg K, Granger CB, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66. (Pubitemid 37093915)
30. Fox KM; EURopean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
31. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2005;45:198-202. (Pubitemid 40179960)
32. Burgess E, Muirehead N, de Cotret PR, et al; the SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal doses of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009;20:893-900.
33. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008;51:714-25.
34. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008;26:1282-9.
35. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;33: b1665.
36. Haute Autorité de Santé (HAS). Les inhibiteurs du système rénine-angiotensine dans l'HTA essentielle non compliquée. Comment choisir entre IEC et sartans? Bon usage du médicament. Octobre 2008. www.has-sante.fr
37. Krummel T, Faller AL, Hannedouche T. Double blocage du système rénine angiotensine dans la néphropathie diabétique: faits et fictions ! Médecine des maladies Métaboliques 2009;3:178-83.
38. Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.